Alqatari S.G.,July 2025 . .Pharmacologic disruption: how emerging weight loss therapies are challenging bariatric surgery guidelines. ” Medicina, 61(7) : 1292.
.2025 .Obesity and Overweight. Accessed August, : .
Dale K.S. . .Sustainability of lifestyle changes following an intensive lifestyle intervention in insulin resistant adults: follow-up at 2-years. Asia Pacific Journal of Clinical Nutrition, 18(2009) : 114-120.
Dawwas G.K.,Samuels J.M.,Stein C.M.,July C.M. .2025 .Shifting obesity treatment paradigms: trends of glucagon-like peptide1 receptor agonists and bariatric surgery in the United States. , : .
Stenberg E.,Näslund E.,April 2023 . .Major adverse cardiovascular events among patients with type-2 diabetes: a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment. International Journal of Obesity, 47(4) : 251-256.
Lin K. .2024 .Metabolic bariatric surgery in the era of GLP-1 receptor agonists for obesity management. ” JAMA Network Open, 41380(10) : e2441380.
Mainous A.G. .2012 .The American Journal of Gastroenterology. , 365(8) : 1218-1223.
Primomo J.A.,November 2016 .2016 .Decreased access to bariatric care: an analysis of referral practices to bariatric specialists.” Surgery for Obesity and Related Diseases. , 08(9) : 1725-1730.
Messiah S.E. .2025 .Metabolic and bariatric surgery utilization in the era of glucagon-like peptide-1 receptor agonists among adolescents versus adults. The Journal of Pediatrics, 114564 : 114564.
Pipek L.Z.,April 2024 . .Surgery is associated with better long-term outcomes than pharmacological treatment for obesity: a systematic review and meta-analysis. ” Scientific Reports, 14(1) : 9521.
Cotugno M.,April 2015 . .Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation. ” Acta Diabetologica, 52(2) : 331-336.
Dicker D.,June 2024 .2024 .Bariatric metabolic surgery vs glucagon-like peptide-1 receptor agonists and mortality. ” JAMA Network Open, 15392(6) : e2415392.
Sagy Wolff,Y. Wolff .2025 .Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer. ” EClinicalMedicine, 103213 : 103213.
Wu T. .2022 .The comparative effects of metabolic surgery, SGLT2i or GLP-1RA in patients with obesity and type 2 diabetes.” Surgery for Obesity and Related Diseases. , 02(6) : 762-771.
Yong S.,Wang J.,Li J. .2012 .“Remission of insulin resistance in type 2 diabetic patients after gastric bypass surgery or exenatide therapy. ” Obesity Surgery, 22 : 1060-1067.
Valderas J.P. .2016 .GLP-1 receptor agonist therapy induces a greater reduction in glycaemic variability compared to gastric bypass in type 2 diabetic patients. ” Diabetologia, 59 : S331.
Husain M. .2020 .Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. ” Diabetes, Obesity and Metabolism, 22 : 442-451.
Ascandar N. .1960 .Clinical outcomes after hospitalization for acute coronary syndrome in patients treated with semaglutide versus bariatric surgery. ” HCA Healthcare Journal of Medicine, 6(3) : 2689-0216.
Zhang Y. .2025 .The epidemiology, clinical characteristics and burden of heart failure with or without obesity in US patients. ” Current Medical Research and Opinion, August, 2535464 : 1-15.
Haseeb M.,April 2024 .2024 .Semaglutide vs endoscopic sleeve gastroplasty for weight loss. ” JAMA Network Open, 6221(4) : e246221.